ES2954456T3 - Análisis digital de células tumorales circulantes en muestras de sangre - Google Patents

Análisis digital de células tumorales circulantes en muestras de sangre Download PDF

Info

Publication number
ES2954456T3
ES2954456T3 ES16769818T ES16769818T ES2954456T3 ES 2954456 T3 ES2954456 T3 ES 2954456T3 ES 16769818 T ES16769818 T ES 16769818T ES 16769818 T ES16769818 T ES 16769818T ES 2954456 T3 ES2954456 T3 ES 2954456T3
Authority
ES
Spain
Prior art keywords
primer
seq
cancer
cdna
ctc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16769818T
Other languages
English (en)
Spanish (es)
Inventor
Daniel A Haber
Ravi Kapur
Mehmet Toner
Shyamala Maheswaran
Xin Hong
David Tomoaki Miyamoto
Kwan Tanya Todorova
Sarah Javaid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2954456T3 publication Critical patent/ES2954456T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/159—Microreactors, e.g. emulsion PCR or sequencing, droplet PCR, microcapsules, i.e. non-liquid containers with a range of different permeability's for different reaction components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/60—Detection means characterised by use of a special device
    • C12Q2565/629—Detection means characterised by use of a special device being a microfluidic device
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES16769818T 2015-03-25 2016-03-25 Análisis digital de células tumorales circulantes en muestras de sangre Active ES2954456T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562137891P 2015-03-25 2015-03-25
US201562219339P 2015-09-16 2015-09-16
US201562253619P 2015-11-10 2015-11-10
PCT/US2016/024367 WO2016154600A1 (en) 2015-03-25 2016-03-25 Digital analysis of circulating tumor cells in blood samples

Publications (1)

Publication Number Publication Date
ES2954456T3 true ES2954456T3 (es) 2023-11-22

Family

ID=56977798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16769818T Active ES2954456T3 (es) 2015-03-25 2016-03-25 Análisis digital de células tumorales circulantes en muestras de sangre

Country Status (10)

Country Link
US (3) US20180057889A1 (cg-RX-API-DMAC7.html)
EP (1) EP3274476B1 (cg-RX-API-DMAC7.html)
JP (2) JP7144934B2 (cg-RX-API-DMAC7.html)
KR (1) KR102502087B1 (cg-RX-API-DMAC7.html)
CN (1) CN107614698A (cg-RX-API-DMAC7.html)
AU (2) AU2016238253B2 (cg-RX-API-DMAC7.html)
CA (1) CA2980562A1 (cg-RX-API-DMAC7.html)
ES (1) ES2954456T3 (cg-RX-API-DMAC7.html)
IL (1) IL254639B (cg-RX-API-DMAC7.html)
WO (1) WO2016154600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107326085B (zh) 2012-02-03 2022-05-03 加州理工学院 多路生化测定中信号的编码和解码
CN107614698A (zh) 2015-03-25 2018-01-19 通用医疗公司 对血液样品中的循环肿瘤细胞的数字分析
US11371101B2 (en) 2016-10-27 2022-06-28 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
US20180252722A1 (en) * 2017-03-05 2018-09-06 Yan Wang PCR-based Method for Counting Circulating Tumor Cells
US11597963B2 (en) * 2017-11-09 2023-03-07 Biomillenia Sas Microbial selection system
WO2019165242A1 (en) * 2018-02-23 2019-08-29 Paraskevi Giannakakou Assay for detection of androgen receptor variants
CN108535145A (zh) * 2018-03-09 2018-09-14 深圳市瑞图生物技术有限公司 快速检测外周血液中网织红细胞数量的方法及装置
CN112424377A (zh) 2018-04-17 2021-02-26 克罗玛科德公司 用于多重分析的方法和系统
CN110456034B (zh) * 2018-05-07 2022-07-22 上海市第十人民医院 一种循环肿瘤细胞的检测方法
US20210172950A1 (en) 2018-06-29 2021-06-10 The General Hospital Corporation Isolating and analyzing rare brain-derived cells and particles
US12203129B2 (en) * 2018-07-03 2025-01-21 ChromaCode, Inc. Formulations and signal encoding and decoding methods for massively multiplexed biochemical assays
WO2020055954A2 (en) * 2018-09-11 2020-03-19 The General Hospital Corporation Methods for detecting liver diseases
KR102380529B1 (ko) * 2020-04-29 2022-03-31 인제대학교 산학협력단 전이성 전립선 암의 진단 및 예후 예측을 위한 혈중종양세포 기반 바이오 마커 조성물
CN112662774A (zh) * 2021-01-12 2021-04-16 南方医科大学南方医院 一种肝癌循环肿瘤细胞标志物及其应用
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用
DE102022211089A1 (de) * 2022-10-19 2024-04-25 Robert Bosch Gesellschaft mit beschränkter Haftung Kombinierte Zellspezifische Markierung und Anreicherung von Biomarkern

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
US8535A (en) 1851-11-18 Stove-geate
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
WO2002012328A2 (en) * 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
EP1399593A2 (en) 2001-05-16 2004-03-24 Novartis AG Genes expressed in breast cancer as prognostic and therapeutic targets
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070026417A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2006121991A2 (en) 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
CA2652052A1 (en) * 2006-05-16 2007-11-29 Nugen Technologies, Inc. Nucleic acid separation and purification method based on reversible charge interactions
EP2589668A1 (en) * 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US9625454B2 (en) * 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
WO2011112903A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
AU2015268617A1 (en) 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
CA2793133C (en) 2010-03-31 2019-08-20 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
US9650629B2 (en) * 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
AU2011291599B2 (en) 2010-08-18 2015-09-10 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2771685B1 (en) * 2011-10-24 2018-06-13 The General Hospital Corporation Biomarkers of cancer
WO2014008155A1 (en) 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
US10161007B2 (en) * 2012-08-13 2018-12-25 The Regents Of The University Of California Methods and systems for detecting biological components
AU2013315128B2 (en) 2012-09-14 2019-01-03 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
WO2014165762A1 (en) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Rare cell analysis after negative selection
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3560591B1 (en) 2013-10-18 2021-02-17 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
BR112016024332A2 (pt) 2014-05-21 2017-08-15 Hoffmann La Roche métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização
WO2016094904A1 (en) 2014-12-12 2016-06-16 Celcuity Llc Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
US20180057899A1 (en) 2015-02-20 2018-03-01 Comelz S.P.A. Method for cutting natural hides and the like
LT3268493T (lt) 2015-03-12 2022-03-10 Janssen Pharmaceutica Nv Viso kraujo mrnr žymenys, skirti prostatos vėžio prognozavimui, ir jo nustatymo būdai
CN107614698A (zh) 2015-03-25 2018-01-19 通用医疗公司 对血液样品中的循环肿瘤细胞的数字分析
US11371101B2 (en) 2016-10-27 2022-06-28 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Also Published As

Publication number Publication date
JP7203128B2 (ja) 2023-01-12
US20180057889A1 (en) 2018-03-01
AU2016238253A1 (en) 2017-10-19
AU2022231734A1 (en) 2022-11-10
US20240132969A1 (en) 2024-04-25
EP3274476A1 (en) 2018-01-31
WO2016154600A1 (en) 2016-09-29
KR20170131516A (ko) 2017-11-29
US20210189501A1 (en) 2021-06-24
JP2021087428A (ja) 2021-06-10
CN107614698A (zh) 2018-01-19
IL254639A0 (en) 2017-11-30
KR102502087B1 (ko) 2023-02-20
US11898209B2 (en) 2024-02-13
EP3274476B1 (en) 2023-06-07
AU2016238253B2 (en) 2022-06-16
JP2018513679A (ja) 2018-05-31
EP3274476A4 (en) 2018-08-29
HK1249553A1 (en) 2018-11-02
CA2980562A1 (en) 2016-09-29
JP7144934B2 (ja) 2022-09-30
IL254639B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
ES2954456T3 (es) Análisis digital de células tumorales circulantes en muestras de sangre
JP7441907B2 (ja) 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析
Sun et al. Coupling lipid labeling and click chemistry enables isolation of extracellular vesicles for noninvasive detection of oncogenic gene alterations
ITTO20080814A1 (it) Metodo per l'individuazione, selezione e analisi di cellule tumorali
US12292443B2 (en) Circulating tumor cell based biomarker composition for diagnosis and prognosis of metastatic prostate cancer
WO2020010311A2 (en) Viral oncogene influences and gene expression patterns as indicators of early tumorigenesis
US20180252722A1 (en) PCR-based Method for Counting Circulating Tumor Cells
Quek et al. Processing of voided urine for prostate cancer RNA biomarker analysis
Bhan et al. Liquid biopsy in hepatocellular carcinoma
CN110747275B (zh) 肿瘤细胞标记分子及其应用
Zhou et al. Protocol to dissociate and isolate wide-diversity single cells by density gradient centrifugation from human hepatoblastoma tissue
HK1249553B (en) Digital analysis of circulating tumor cells in blood samples
JPWO2015129646A1 (ja) Ｄｎａメチル化解析方法ならびにｃｙｐ３ａ４発現量推定方法
Jepson Single-cell MicroRNA Sequencing of Circulating Tumour Cells: A New Tool for Monitoring Prostate Cancer
Telkoparan Akillilar et al. Role of circulating tumor cells and cell-free tumor deoxyribonucleic acid fragments as liquid biopsy materials in breast oncology